Leick, Katie M.
Kazarian, Austin G.
Rajput, Maheen
Tomanek-Chalkley, Ann
Miller, Ann
Shrader, Hannah R.
McCarthy, Ashley
Coleman, Kristen L.
Kasi, Pashtoon M.
Chan, Carlos H. F.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (T35 HL007485)
National Cancer Institute (P30 CA086862)
National Institutes of Health (T32 CA078586)
Article History
Received: 26 February 2020
Accepted: 27 June 2020
First Online: 9 July 2020
Disclosure
: P.M.K.: consultancy/advisory board (Taiho, Ipsen, Foundation Medicine, Natera); Honoraria (AstraZeneca, Foundation Medicine, Natera). Foundation Medicine, a company focusing on genomics and ctDNA in blood/tissue, is not directly related to the submitted work but to ctDNA testing. Natera, a company focusing on ctDNA for stage II/III colorectal cancer, is not directly related to the submitted work but to the field of liquid biopsies. All other authors declare that they have no conflicts of interest.